Lupus Therapeutics announced is embarking on a clinical study to assess the potential benefit of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in people with lupus.

The study will be designed and conducted in collaboration with Lupus Therapeutics' Lupus Clinical Investigators Network (LuCIN) comprised of 57 of the most prestigious academic medical centers in the United States and Canada. Approximately 20,000 lupus patients are part of the network.

This study is intended to follow up on anecdotal data from several academic centers within LuCIN. From Cedars-Sinai in Los Angeles, rheumatologist Dr. Daniel J. Wallace, who is also a Lupus Research Alliance Board of Directors member, reports only one patient with lupus out of 1,000+ admissions and screenings for COVID-19 to date. And, of the 800 patients Dr. Wallace regularly treats with lupus, none have developed COVID-19.

The LRA will keep the lupus community posted about the progress of this highly relevant study for the population we serve.

"This initiative is being done in response to reports that hydroxychloroquine and perhaps other immuno-suppressive agents taken by lupus patients may offer some benefit against COVID-19," said Albert Roy, Executive Director, Lupus Therapeutics. "We are in early stages and it is unclear what our results will find -- whether these drug therapies alone, self-quarantining or a combination of both – are having the most impact."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.